Blood Cancer Journal

Article	Citations
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort	149
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma	143
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study	136
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report	134
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M	118
Disparities in time to treatment with oral antimyeloma medications	112
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib	110
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity	104
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells	102
A multiparametric niche-like drug screening platform in acute myeloid leukemia	99
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT	99
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes	95
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study	94
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine	82
Genomic landscape of hyperleukocytic acute myeloid leukemia	79
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma	77
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma	77
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid	75
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes	73
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease	69
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm	66
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	66
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study	66
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients	66
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency	65

Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management	64
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma	64
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma	63
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia	60
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia	57
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review	53
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial	53
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy	50
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression	49
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma	46
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study	46
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier	46
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis	46
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma	43
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma	43
RSK1 dependency in FLT3-ITD acute myeloid leukemia	43
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia	42
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review	42
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment	41
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity	40
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome	40
Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data	40
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations	40
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis	39
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma	39
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma	39
Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia	37
Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models	37
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial	37
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors	37
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma	36
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma	36
Characteristics and predictors of central nervous system relapse in newly diagnosed acute promyelocytic leukemia in the era of arsenic: a 13-year monocenter cohort study	35
Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?	33
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia	33
Bispecific antibodies in the treatment of multiple myeloma	33
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older	33
Management of chronic myeloid leukemia in 2023 – common ground and common sense	33
Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia	32
The long shadow of socioeconomic deprivation over the modern management of acute myeloid leukemia: time to unravel the challenges	32
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study	32
Deep immune cell profiling in blood and bone marrow of early stage monoclonal gammopathy: an iStopMM and ECRIN-M3 collaborative study	31
Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk	31
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial	30
Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection	30
CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma	30
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999	30
Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases	29
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up	29
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians	29

Risk of lymphoid malignancy associated with cancer predisposition genes	29
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials	29
Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years	28
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection	28
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)	28
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial	27
Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis	27
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage	27
Primary cells from patients with adult T cell leukemia/lymphoma depend on HTLV-1 Tax expression for NF-κB activation and survival	27
Smoldering multiple myeloma current treatment algorithms	27
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study	26
Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid	26
Correction: TET2 deficiency promotes MDS-associated leukemogenesis	26
Donor cell-derived genetic abnormalities after sex mismatched allogeneic cell transplantation: a unique challenge of donor cell leukemia	26
Drug development in higher-risk myelodysplastic syndromes	26
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial	26
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation	25
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma	24
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk	24
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms	24
Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study	24
MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma	24
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial	24
Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma	24
Reducing the risks of nuclear war—the role of health professionals	23
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients	23
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients	23
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities	23
Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019	22
Conditional relative survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands	22
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia	22
Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms	22
Late effects in survivors of infant acute lymphoblastic leukaemia—a study of the Australian and New Zealand Children’s Haematology/Oncology Group	22
Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy	22
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry	22
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study	21
JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation	21
Breakthrough infections in MPN-COVID vaccinated patients	21
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment	21
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome	21
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes	21
Haploidentical vs matched sibling donor transplant for paroxysmal nocturnal haemoglobinuria: A multicenter study	20
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma	20
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?	20
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms	20
Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy	19
Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota	19
Cutaneous manifestations of monoclonal gammopathy	19
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy	19
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib	19
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation	19
Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry	19
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm	19
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century	19
Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study	19
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma	19
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation	19
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms	19
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages	19
Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies	18
Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML	18
The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis	18
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab	18
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in t	18
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies	17
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression	17
Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma	17
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera	17
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis	17
Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancy	16
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience	16
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement	16
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia	16
MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma	16
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party	16
To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia	16
Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study	16
Survival trends in hematological malignancies in the Nordic countries through 50 years	16
The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders	16
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms	16

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial	16
Drug importation: limitations of current proposals and opportunities for improvement	16
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis	15
Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study	15
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study	15
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison	15
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases	15
Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study	15
Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival	15
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)	15
Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms	15
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm	15
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group	14
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation	14
Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data	14
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies	14
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma	14
Patient preferences for intervention in the setting of precursor multiple myeloma	14
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study	14
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma	14
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements	14
DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation	14
Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia	14
The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma	14
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma	14
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era	14
The expanding CML treatment landscape: an introspective commentary	14
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia	13
Conditional survival in multiple myeloma and impact of prognostic factors over time	13
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee	13
I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients	13
Mode of progression in smoldering multiple myeloma: a study of 406 patients	13
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021	13
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome	13
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy	13
An atlas of the bone marrow bone proteome in patients with dysproteinemias	13
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse	13
Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study	13
Resistance to targeted therapies: delving into FLT3 and IDH	13
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission	13
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel	13
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target	12
Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”	12
Venetoclax ex vivo functional profiling predicts improved progression-free survival	12
Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study	12
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?	12
Prevalence of monoclonal gammopathy of undetermined significance (MGUS) at HIV diagnosis in individuals 18–40 years old: a possible HIV indicator condition	12
Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial	12
Extramedullary disease in multiple myeloma	12
Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL	12
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma	12
A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma	12
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study	12
Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma	12
Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study	12
Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes	12
Utility of flow cytometry screening before MRD testing in multiple myeloma	12